UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-19

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to investigate the inflammatory response in a subclinical study within 1 year of Neuroncell-EX infusion in participants with acute ischemic stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke

NCT01091701

Stroke

WITHDRAWN PHASE1/PHASE2

Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke

NCT04811651

Ischemic Stroke

COMPLETED PHASE2

Stem Cell Infusion in the Treatment of Patients with Neurological Sequelae After Ischemic Stroke

NCT05292625

Ischemic Stroke

COMPLETED PHASE1/PHASE2

A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke.

NCT01832428

Stroke,

UNKNOWN PHASE1/PHASE2

Autologous Stem Cell Therapy in Stroke

NCT02245698

Stroke

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Ischemic stroke is a serious cerebrovascular disease with high morbidity and disability worldwide. Despite the great efforts that have been made, the prognosis of stroke patients remains unsatisfactory. Mesenchymal stem cells (MSCs) therapy is an emerging treatment studied in various medical conditions including autoimmune, inflammatory as well as central nervous system diseases. The mechanism of MSCs in the treatment of ischemic stroke involved with immune regulation, neuroprotection, angiogenesis, and neural circuit reconstruction. A large number of preclinical data have proved the feasibility of MSCs in the treatment of stroke where the administration of MSCs can alleviate neurological deficits. Similarly, a number of clinical trials have also proved the effectiveness and safety of MSCs in the treatment of stroke. Among these is a phase 2, single-center, assessor-blinded randomized controlled study by investigators using bone marrow-derived MSCs in patients with subacute middle cerebral artery infarct. The investigators demonstrated the safety, tolerability, and efficacy of intravenous infusion of MSCs with significant improvement in median infarct volume (Law et al., 2021).

Objective: To determine the efficacy of intravenous infusion of allogeneic Cytopeutics umbilical cord mesenchymal stem cells (Neuroncell-EX) in participants with acute ischemic stroke.

Study Design: This is a phase II-III double-blind randomized controlled study involving 80 participants, diagnosed with acute ischemic stroke admitted to HCTM-UKM. Investigational treatment arm (Group A-MSCs) consist of 40 participants will receive Neuroncell-EX whereas control treatment arm (Group B-Control) consist of 40 participants will receive placebo. Both groups will also receive standard medical care for acute stroke. Efficacy assessments will include Barthel index (BI) and modified Rankin Scale (mRS), Functional Magnetic Resonance Imaging (fMRI) and blood tests including biomarkers within 12 months follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neuroncell-EX

Umbilical cord-derived mesenchymal stem cells

Group Type EXPERIMENTAL

Neuroncell-EX

Intervention Type BIOLOGICAL

Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.

Control

Normal saline

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuroncell-EX

Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.

Intervention Type BIOLOGICAL

Placebo

Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must be aged ≥ 18 years old.
2. Patients with acute ischemic stroke symptom onset within 4 weeks.
3. Patients diagnosed with "moderate to severe" based on NIHSS (6-24) at the time of recruitment.
4. Patients who are not eligible for thrombolysis or thrombectomy.
5. Written informed consent by the patient or next-of-kin.

Exclusion Criteria

1. Patients who are medically unfit such as those who are haemodynamically unstable or whose general condition is deteriorating.
2. Patients with transient ischemic attack (TIA).
3. Patients who have been diagnosed with malignancy (past or present) or primary haematological disorders.
4. Patients who have renal impairment with serum creatinine more than 200 µmol/l or creatinine clearance less than 30 ml/min.
5. Patients who have liver impairment with serum aspartate transaminase (AST) and alanine aminotransferase (ALT) two times greater than upper normal limit.
6. Patients who are pregnant or are breastfeeding.
7. Patients diagnosed with brain hemorrhage or other pathological brain disorders such as vascular malformation (brain arteriovenous malformation), tumor, abscess, cardiogenic, inflammatory and infectious cerebral embolism or other common non- ischemic brain diseases, or diagnosed with severe brain atrophy, as determined by CT or MRI scans.
8. Patients diagnosed/suspected diagnosis with acute coronary syndrome.
9. Patients with congestive cardiac failure.
10. Patients with history of confirmed or suspected pulmonary embolism or chronic obstructive pulmonary disease (COPD).
11. Patients with mental, cognitive or psychological disorders that affects their understanding and adherence to research procedures and follow-ups.
12. Patients that are undergoing experimental drug or instrument testing or have participated in other clinical drug trials in the past 3 months.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No